Compare IMVT & LGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMVT | LGN |
|---|---|---|
| Founded | 2018 | 1963 |
| Country | United States | United States |
| Employees | N/A | 7000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.4B |
| IPO Year | 2019 | N/A |
| Metric | IMVT | LGN |
|---|---|---|
| Price | $31.22 | $83.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | $33.00 | ★ $59.50 |
| AVG Volume (30 Days) | ★ 2.4M | 1.4M |
| Earning Date | 05-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $53.66 |
| Revenue Next Year | N/A | $11.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.32 | $28.31 |
| 52 Week High | $36.29 | $107.24 |
| Indicator | IMVT | LGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 47.43 |
| Support Level | $22.84 | $78.88 |
| Resistance Level | $36.29 | $90.35 |
| Average True Range (ATR) | 1.95 | 4.67 |
| MACD | -0.20 | -0.86 |
| Stochastic Oscillator | 50.26 | 39.61 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Legence Corp is a provider of engineering, installation, and maintenance services for critical systems in buildings. It focuses on sectors that have technically demanding buildings, including technology, life sciences, healthcare, and education. Legence specializes in designing, fabricating, and installing complex heating, ventilation, and air conditioning (HVAC), process piping, and other mechanical, electrical, and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting, and building controls in existing facilities to enhance building performance, reliability, and efficiency. The services are mainly provided on a fixed price basis. The company has two reportable segments: Installation and Maintenance, which generates the maximum revenue, and Engineering and Consulting.